Efficacy and safety of Toludesvenlafaxine extended-release tablets in the treatment of treatment-resistant depression.

ABSTRACT:

Background

Treatment-resistant depression (TRD) is a major challenge in clinical psychiatry, characterized by insufficient response to at least two different classes of antidepressants. Despite advances in treatment, many TRD patients continue to experience significant symptoms and reduced quality of life. The study aims to provide an exploratory assessment of toludesvenlafaxine hydrochloride sustained-release tablets for efficacy and safety in TRD.

Methods

We conducted an open-label, single-arm, exploratory 8-week study in adults with TRD (n = 31) receiving Toludesvenlafaxine. The primary endpoint was the change in the Montgomery-Asberg Depression Rating Scale (MADRS) score from baseline to week 8. Secondary endpoints included changes in anxiety, quality of life, and functi

SUBMITTER: Qi Z 

PROVIDER: S-EPMC12752360 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature